The Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2 (I-SPY 2) trial is a biomarker-rich, neoadjuvant, adaptively randomized, multicenter, phase 2 platform trial designed for the treatment of locally advanced breast cancer.10 Women enrolled in the trial have clinically hormone receptor (HR)–negative/ERBB2 (formerly HER2 or HER2/neu)–positive or genomically (based on molecular subtyping) high-risk breast cancers and are adaptively randomized to different treatment arms based on their tumor subtype. This evidence concerns the gene ERBB2 and neoplasm.